靶向治疗的潜在风险。 - Suppr

Suppr

超能文献

The possible perils of targeted therapy.

作者信息

Duffner U, Abdel-Mageed A, Younge J, Tornga C, Scott K, Staddon J, Elliott K, Stumph J, Kidd P

机构信息

Division of Pediatric Blood & Bone marrow Transplantation at Helen DeVos Children's Hospital, Grand Rapids, MI, USA.

Spectrum Health and Michigan State University, Department of Pediatrics & Human Development, Grand Rapids, MI, USA.

出版信息

Leukemia. 2016 Jul;30(7):1619-21. doi: 10.1038/leu.2016.18. Epub 2016 Feb 9.

DOI:10.1038/leu.2016.18

PMID:26859079

Abstract

摘要

相似文献

The possible perils of targeted therapy.靶向治疗的潜在风险。

Leukemia. 2016 Jul;30(7):1619-21. doi: 10.1038/leu.2016.18. Epub 2016 Feb 9.

Blinatumomab significantly improves overall survival.博纳吐单抗显著提高总生存期。

Lancet Oncol. 2017 Apr;18(4):e203. doi: 10.1016/S1470-2045(17)30183-3. Epub 2017 Mar 10.

Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in -rearranged infant ALL.在 BCR-ABL 重排婴儿 ALL 中，blinatumomab 诱导的 ALL 至 AML 转换后，谱系转换自发逆转。

Blood Adv. 2018 Jun 26;2(12):1382-1385. doi: 10.1182/bloodadvances.2018018093.

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.复发/难治性B细胞前体急性淋巴细胞白血病儿科患者接受博纳吐单抗治疗后的生存率

Blood Cancer J. 2018 Aug 22;8(9):80. doi: 10.1038/s41408-018-0117-0.

Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR-T cell therapy in KMT2A-rearranged, therapy-related acute lymphoblastic leukemia.在KMT2A重排、治疗相关的急性淋巴细胞白血病中，先用帕博西尼和化疗，然后用贝林妥欧单抗巩固治疗，再进行CAR-T细胞治疗。

Pediatr Blood Cancer. 2024 Jun;71(6):e30964. doi: 10.1002/pbc.30964. Epub 2024 Mar 21.

Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy.在CD19靶向治疗下，B急性淋巴细胞白血病向急性单核细胞白血病发生谱系转换，伴有持续的t(4;11)(q21;q23)和细胞遗传学演变。

Ann Hematol. 2017 Sep;96(9):1579-1581. doi: 10.1007/s00277-017-3050-6. Epub 2017 Jun 20.

Phase 1/2 study of blinatumomab in relapsed paediatric ALL.博纳吐单抗用于复发儿童急性淋巴细胞白血病的1/2期研究。

Lancet Oncol. 2016 Dec;17(12):e525. doi: 10.1016/S1470-2045(16)30580-0. Epub 2016 Nov 11.

Blinatumomab for paediatric mixed phenotype acute leukaemia.博纳吐单抗治疗儿童混合表型急性白血病。

Br J Haematol. 2021 Oct;195(2):289-292. doi: 10.1111/bjh.17707. Epub 2021 Jul 12.

Inv(11)(q21q23); KMT2A-MAML2, a Recurrent Genetic Abnormality in T-Cell Therapy-related Acute Lymphoblastic Leukemia.inv(11)(q21q23);KMT2A-MAML2，一种与T细胞治疗相关的急性淋巴细胞白血病中的复发性基因异常。

J Pediatr Hematol Oncol. 2020 May;42(4):e258-e261. doi: 10.1097/MPH.0000000000001572.

Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement.在复发的无MLL重排的普通急性淋巴细胞白血病患者接受博纳吐单抗治疗期间的谱系转换

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26594. Epub 2017 Apr 28.

引用本文的文献

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.EVOLVE项目：白血病免疫治疗后谱系转换的国际分析，一种新出现的复发形式

Blood. 2025 Jul 24;146(4):437-455. doi: 10.1182/blood.2024026655.

Evolutionary genomic analysis for ALL.急性淋巴细胞白血病的进化基因组分析

Nat Cancer. 2023 Aug;4(8):1058-1059. doi: 10.1038/s43018-023-00605-z.

Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens.通过全身递送肿瘤相关抗原增强过继性 CD8 T 细胞治疗。

Sci Rep. 2021 Oct 5;11(1):19794. doi: 10.1038/s41598-021-99347-0.

Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation.单倍体造血干细胞移植后HLA缺失复发的博纳吐单抗治疗

Am J Cancer Res. 2021 Jun 15;11(6):3111-3122. eCollection 2021.

[CD19 antigen loss after treatment of Bispecific T-cell Engager and effective response to salvage bispecific CAR-T therapy in B cell acute lymphoblastic leukemia: a case report and literature review].[双特异性T细胞衔接器治疗后CD19抗原丢失及对挽救性双特异性嵌合抗原受体T细胞疗法在B细胞急性淋巴细胞白血病中的有效反应：一例报告及文献综述]

Zhonghua Xue Ye Xue Za Zhi. 2020 Apr 14;41(4):282-286. doi: 10.3760/cma.j.issn.0253-2727.2020.04.004.

Immunotherapy- (Blinatumomab-) Related Lineage Switch of Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia.免疫疗法（博纳吐单抗相关）导致重排的B淋巴细胞白血病转变为急性髓系白血病/髓系肉瘤，随后又转变为B/髓系混合表型急性白血病。

Case Rep Hematol. 2019 Dec 7;2019:7394619. doi: 10.1155/2019/7394619. eCollection 2019.

Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.blinatumomab诱导的伴有t(4:11)(q21;q23) KMT2A/AFF1的B淋巴细胞白血病向侵袭性急性髓系白血病的谱系转换：转换前后的表型、细胞遗传学和分子分析

Blood Cancer J. 2017 Sep 15;7(9):e607. doi: 10.1038/bcj.2017.89.

Antigen Loss Variants: Catching Hold of Escaping Foes.抗原丢失变体：抓住逃脱的敌人

Front Immunol. 2017 Feb 24;8:175. doi: 10.3389/fimmu.2017.00175. eCollection 2017.

本文引用的文献

Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.抗CD19双特异性T细胞衔接器（BiTE）的临床概述以及抗CD33双特异性T细胞衔接器（BiTE）的体外数据，作为血液系统恶性肿瘤中T细胞重定向的实例

Mol Immunol. 2015 Oct;67(2 Pt A):58-66. doi: 10.1016/j.molimm.2015.02.033. Epub 2015 Apr 13.

MLL leukemia and future treatment strategies.MLL 白血病与未来的治疗策略。

Arch Pharm (Weinheim). 2015 Apr;348(4):221-8. doi: 10.1002/ardp.201400449. Epub 2015 Mar 4.

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.抗 CD19 双特异性 T 细胞衔接蛋白blinatumomab 的 II 期临床试验显示，复发或难治性 B 前体急性淋巴细胞白血病患者有血液学和分子缓解。

J Clin Oncol. 2014 Dec 20;32(36):4134-40. doi: 10.1200/JCO.2014.56.3247. Epub 2014 Nov 10.

CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage.CD2 阳性 B 细胞前体急性淋巴细胞白血病向单核细胞系早期分化。

Leukemia. 2014 Mar;28(3):609-20. doi: 10.1038/leu.2013.354. Epub 2013 Nov 25.

Lineage switch in childhood acute leukemia: an unusual event with poor outcome.儿童急性白血病中的谱系转换：一种不良预后的不常见事件。

Am J Hematol. 2012 Sep;87(9):890-7. doi: 10.1002/ajh.23266. Epub 2012 Jun 8.

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.针对化疗耐药的 B 系急性淋巴细胞白血病患者微小残留病灶的 T 细胞结合抗体blinatumomab 的靶向治疗可带来高缓解率和延长无白血病生存。

J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.

Acute monocytic leukaemia originating from MLL-MLLT3-positive pre-B cells.

Br J Haematol. 2010 Sep;150(5):621-3. doi: 10.1111/j.1365-2141.2010.08239.x. Epub 2010 May 20.

Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?正常造血与白血病造血：白血病是干细胞疾病还是干细胞特性的重新获得？

Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1(Suppl 1):11842-9. doi: 10.1073/pnas.2034201100. Epub 2003 Sep 22.

Bipotential B-macrophage progenitors are present in adult bone marrow.双潜能B巨噬细胞祖细胞存在于成年骨髓中。

Nat Immunol. 2001 Jan;2(1):83-8. doi: 10.1038/83210.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验